Discover
LGVN
Longeveron Inc.
0.73
2 x 0.53
2 x 0.92
bid
ask
+
0.03
3.71%
2 @ 04:00 PM
0.73 +0.00 (0.27%)
| Ytd | 44.09% | |
| 1y | -43.04% |
0.71
day range
0.79
0.47
52 week range
1.80
| Open | 0.72 | Prev Close | 0.70 | Low | 0.71 | High | 0.79 | Mkt Cap | 23.04M |
| Vol | 611.65K | Avg Vol | 476.23K | EPS | -1.14 | P/E | N/A | Forward P/E | -1.16 |
| Beta | 0.35 | Short Ratio | 2.03 | Inst. Own | 3.34% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 0.80 | 200-d Avg | 0.74 | 1yr Est | 8.88 |
LGVN News
seekingalpha.com
Longeveron Inc. (LGVN) Shareholder/Analyst Call Prepared Remarks Transcript
Longeveron Inc. (LGVN) Shareholder/Analyst Call Prepared Remarks Transcript
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Can Fite Biopharma (AMEX:CANF) stock moved upwards by 52.0% to $4.52 during Wednesday's
benzinga.com
Longeveron Announces Additional Analysis For Phase 2a Clinical Trial Of Mild Alzheimer's Disease Ste
Poster Presentation (Exhibit Hall) Date:Monday, July 13, 2026Time:7:30am – 4:15pm BSTSession:In-Pers
benzinga.com
Longeveron Granted Small Or Medium-Sized Enterprise Status By European Medicines Agency
According to the EMA, SME Designation has allowed for improved success rate for organizations seekin
benzinga.com
Longeveron CFO Lisa Locklear Plans To Step Down, Effective July 10
https://www.sec.gov/ix?doc=/Archives/edgar/data/1721484/000121390026065788/ea0293758-8k_longeveron.h